Dr. Zanganeh is Founder/CEO of Maky Zanganeh and Associates, which provides consulting services to businesses in product development, research and transactions. She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device and technology industries.
Most recently, Dr. Zanganeh was Chief Operating Officer at Pharmacyclics Inc. where she oversaw all clinical, research, commercial and business-related matters. Under her leadership, the company was able to achieve four FDA labels, with three Breakthrough Therapy Designations, in 14 months; a feat which has never been accomplished by any company before. Dr. Zanganeh also drove the multimillion dollar collaboration and license deal for ibrutinib with Janssen Biotech Inc. in 2011 and the subsequent sale of the company for $21 billion dollars in 2015 to Abbvie Inc.; the second largest biopharma sale ever in the industry. The deal with Janssen Biotech received the award of the “Best Biotech Transaction” in 2011. Under her leadership in 2015, Pharmacyclics was awarded the prestigious Prix Galien for Best Pharmaceutical Agent. This award is the biomedical industry’s highest accolade, the Prix Galien Award recognizes outstanding achievement in the development of new therapies.
Previously (2003-2008), she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates (a private investment firm), President of EMEA / Global VP of Training and Education for Computer Motion, Inc. (Pioneers in Robotic Surgery). Computer Motion, Inc. merged with Intuitive Surgical (ISRG) company in June 2003.
Dr. Zanganeh was awarded her D.D.S. from the Louis Pasteur University, France and an MBA from Schiller International University, France. She is fluent in French, German, Farsi and English. Dr Zanganeh earned the Fierce Biotech "2013 Top women in biotech" award and the E&Y company, Entrepreneur of the Year 2013 award.
Dr. Zanganeh is an active board member for the following companies: Pulse BioScience, Human Longevity Inc., Oxstem ltd. (Oxford), Genoscience (France), and Radial Medical.